---
title: "10:34 ET\n\t\t\t\n\t\t\t\n\t\t\t\tHims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS"
description: "DJS Law Group is investigating Hims & Hers Health, Inc. for potential securities fraud violations, focusing on misleading statements and undisclosed information. The investigation follows Novo Nordisk"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250443741.md"
published_at: "2025-07-28T14:34:10.000Z"
---

# 10:34 ET
			
			
				Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS

> DJS Law Group is investigating Hims & Hers Health, Inc. for potential securities fraud violations, focusing on misleading statements and undisclosed information. The investigation follows Novo Nordisk's termination of its collaboration with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices. This led to a significant drop in Hims & Hers shares by 31.7%. Shareholders who suffered losses are encouraged to contact DJS Law Group for participation in the investigation.

, /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws.

**INVESTIGATION DETAILS:** The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk issued a press release on June 23, 2025, announced that it was terminating its "collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing." According to the press release, "the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." Based on this, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025.

If you are a shareholder who suffered a loss, contact us to participate.

**WHY DJS LAW GROUP?** DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

**CONTACT:**

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: \[email protected\]

SOURCE DJS Law Group LLP

### Related Stocks

- [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA 的打擊行動重塑了 Wegovy 的競爭格局，並增加了諾和諾德投資者的風險 | FDA 對諾和諾德公司 Wegovy 的誤導性廣告的打擊加大了對 GLP-1 營銷的審查，導致來自仿製藥替代品的競爭減少。這一監管變化發生在諾和諾德面臨美國定價壓力可能導致銷售下降的背景下。雖然 FDA 的行動可能在短期內支持 Wegovy | [Link](https://longbridge.com/en/news/275899622.md) |
| 分析 - 美國可能會對 Hims 採取行動，包括在短暫推出 Wegovy 仿製品後進行罰款 | 特朗普政府可能會對 Hims 採取法律行動，因其試圖銷售諾和諾德公司的 Wegovy 減肥藥的複合版本。FDA 已將 Hims 轉交給司法部，因其可能違反《食品、藥品和化妝品法》。Hims 聲稱其產品因患者個性化而合法，但其合法性正受到審查 | [Link](https://longbridge.com/en/news/275888721.md) |
| 期權熱點｜上周五 NBIS 大漲 9%，部分看漲期權飆升 378% | 美東時間 2026-02-13，Nebius 期權總成交 179098 張，看漲期權佔比 71%，看跌期權佔比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) |
| Codeifai 進入由 AI 支持的量子安全市場 | Codeifai Ltd：CODEIFAI 進入人工智能支持的量子安全市場，完成對 AntennaTransfer.Io 的收購，總對價為 130 萬澳元 | [Link](https://longbridge.com/en/news/276015719.md) |
| 施耐德電氣（OTCMKTS:SBGSY）的空頭頭寸減少了 16.8% | 施耐德電氣 (SE)(OTCMKTS:SBGSY) 在 1 月份的空頭頭寸減少了 16.8%，截至 1 月 30 日，短期賣出股票為 197,858 股。根據 862,077 股的平均日交易量，當前的空頭頭寸比率為 0.2 天。分析師對該股 | [Link](https://longbridge.com/en/news/276071356.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.